Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Free Access

Robust Age at Onset Linkage Analysis in Nuclear Families

Callegaro A. · van Houwelingen J.C. · Houwing-Duistermaat J.J.

Author affiliations

Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands

Corresponding Author

Andrea Callegaro

Department of Medical Statistics and Bioinformatics

Leiden University Medical Center, S-5-P, PO Box 9600

NL–2300 RC Leiden (The Netherlands)

Tel. +31 71 526 9718, Fax +31 71 526 8280, E-Mail a.callegaro@lumc.nl

Related Articles for ""

Hum Hered 2010;69:80–90

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Objective: Standard methods for linkage analysis ignore the phenotype of the parents when they are not genotyped. However, this information can be useful for gene mapping. In this paper we propose methods for age at onset genetic linkage analysis in sibling pairs, taking into account parental age at onset. Methods:Two new score statistics are derived, one from an additive gamma frailty model and one from a log-normal frailty model. The score statistics are classical non-parametric linkage (NPL) statistics weighted by a function of the age at onset of the four family members. The weight depends on information from registries (age-specific incidences) and family studies (sib-sib and father-mother correlation). Results:In order to investigate how age at onset of sibs and their parents affect the information for linkage analysis the weight functions were studied for rare and common disease models, realistic models for breast cancer and human lifespan. We studied the performance of the weighted NPL methods by simulations. As illustration, the score statistics were applied to the GAW12 data. The results show that it is useful to include parental age at onset information in genetic linkage analysis.

© 2009 S. Karger AG, Basel


References

  1. Beekman M, Blauw GJ, Houwing-Duistermaat JJ, Brandt BW, Westendorp RGJ, Slagboom PE: Chromosome 4q25, microsomal transfer protein gene, and human longevity: novel data and a meta-analysis of association studies. J Gerontol A Biol Sci Med Sci 2006;61:355–362.
  2. Lebrec J, Putter H, Houwelingen JC: Score test for detecting linkage to complex traits in selected samples. Genet Epidemiol 2004;27:97–108.
  3. Commenges D: Robust genetic linkage analysis based on a score test of homogeneity: the weighted pairwise correlation statistic. Genet Epidemiol 1994;11:189–200.
  4. Li H: The additive genetic gamma frailty model for linkage analysis of age-of-onset variation. Ann Hum Genet 1999;63:455–468.
  5. Siegmund KD, Todorov AA: Linkage analysis for diseases with variable age of onset. Hum Hered 2000;50:205–210.
  6. Li H, Zhong X: Multivariate survival models induced by genetic frailties, with application to linkage analysis. Biostatistics 2002;3:57–75.
  7. Li H: An additive genetic gamma frailty model for linkage analysis of diseases with variable age of onset using nuclear families. Lifetime Data Anal 2002;8:315–334.
  8. Houwing-Duistermaat JJ, Callegaro A, Beekman M, Westendorp RG, Slagboom PE, van Houwelingen JC: Weighted statistics for aggregation and linkage analysis of human longevity in selected families: The Leiden Longevity Study. Stat Med 2008;28:140–151.
    External Resources
  9. Callegaro A, van Houwelingen HC, Houwing-Duistermaat JJ: Score test for age at onset genetic linkage analysis in selected sibling-pairs. Stat Med 2009;28:1913–1926.
  10. Pankratz VS, de Andrade M, Therneau TM: Random-effects Cox proportional hazards model: general variance components methods for time-to-event data. Genet Epidemiol 2005;28:97–109.
  11. Lebrec JJ, van Houwelingen HC: Score test for linkage in generalized linear models. Hum Hered 2007;64:5–15.
  12. Almasy L, Terwilliger JD, Nielsen D, Dyer TD, Zaykin D, Blangero J: GAW12: Simulated genome scan, sequence, and family data for a common disease. Genet Epidemiol 2001;21S:332–338.
  13. Tang HK, Siegmund D: Mapping quantitative trait loci in oligogenic models. Biostatistics 2001;2:147–162.
  14. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES: Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347–1363.
  15. Wintrebert CM, Zwinderman AH, Maat-Kievit A, Roos RA, van Houwelingen HC: Assessing genetic effects in survival data by correlating martingale residuals with an application to age at onset of Huntington disease. Stat Med 2006;25:3190–3200.
  16. Blackwelder WC, Elston RC: A comparison of sib-pair linkage tests for disease susceptibility loci. Genet Epidemiol 1985;2:85–97.
  17. Wienke A, Lichtenstein P, Yashin AI: A bivariate frailty model with a cure fraction for modeling familial correlations in diseases. Biometrics 2003;59:1178–1183.
  18. Yashin AI, Begun AZ, Iachine IA: Genetic factors in susceptibility to death: a comparative analysis of bivariate survival models. J Epidemiol Biostat 1999;4:53–60.
  19. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin-rapid analysis of dense genetic maps using sparse gene fl‚ow trees. Nat Genet 2002;30:97–101.
  20. Wallace C, Clayton DG: Appropriate use of information on family history of disease in recruitment for linkage analysis studies. Ann Hum Genet 2006;70:360–371.
  21. Yashin AI, Vaupel JW, Iachine IA: Correlated individual frailty: an advantageous approach to survival analysis of bivariate data. Math Popul Stud1995;5:145–159.
  22. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U: Heritability of death from coronary heart disease: a 36-year follow-up of 20,966 Swedish twins. J Intern Med 2002;252:247–254.
  23. Zahl PH: Frailty modelling for the excess hazard. Stat Med 1997;16:1573–1785.
  24. Jonker MA, Bhulai S, Boomsma DI, Ligthart RS, Posthuma D, Van der Vaart AW: Gamma frailty model for linkage analysis with application to interval-censored migraine data. Biostatistics 2008;10:187–200.
  25. Petersen JH, Andersen PK, Gill RD: Variance components models for survival data. Stat Neerl 1996;50:193–211.
    External Resources
  26. Cox DR: Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972;34:187–220.
    External Resources
  27. Whittemore AS: Genome scanning for linkage: an overview. Am J Hum Genet 1996;59:704–716.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: April 01, 2009
Accepted: July 13, 2009
Published online: December 04, 2009
Issue release date: January 2010

Number of Print Pages: 11
Number of Figures: 6
Number of Tables: 2

ISSN: 0001-5652 (Print)
eISSN: 1423-0062 (Online)

For additional information: https://www.karger.com/HHE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.